E2F3 and neuroblastoma: Neuroblastoma patients with higher expression levels of E2F3 were also had lower event free survival in TARGET, GSE16476, GSE85047 and E-MTAB-1781 datasets, compared with neuroblastoma patients with lower expression levels of E2F3 (Fig. 3c).